alexa Clinical Practices that can Combat Endemic Legal Opioid Dependence: Genetic Addiction Risk Score (GARS)™, KB220Z™, Comprehensive Analysis of Reported Drugs (CARD) and Electrotherapy
ISSN: 2157-7412
Journal of Genetic Syndromes & Gene Therapy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Clinical Practices that can Combat Endemic Legal Opioid Dependence: Genetic Addiction Risk Score (GARS)™, KB220Z™, Comprehensive Analysis of Reported Drugs (CARD) and Electrotherapy

Blum K1-4,7,8,10*, Febo M1, Giordano J2, Hauser M4, Oscar- Berman M5, Smolen A6, Simpatico T7, McLaughlin T9, Dinubile N11 and Roy K12

1Department of Psychiatry and McKnight Brain Institute, University of Florida, College of Medicine, Gainesville, Florida, USA

2G and G Health Care Services LLC, North Miami Beach, Florida, USA

3Department of Nutrigenomics, IGENE, LLC, Austin, Texas

4Dominion Diagnostics, Inc., North Kingstown, Rhode Island, USA

5Department of Psychiatry, Boston University School of Medicine, and VA system, Boston, MA, USA

6Institute of Behavioral genetics, University of Colorado, Boulder, Colorado

7Department of Psychiatry, Human Integrated Services Unit University of Vermont Center for Clinical and Translational Science, College of Medicine, Burlington, VT, USA

8Path Foundation NY, New York, New York, USA

9Center for Psychiatric Medicine, North Andover, Massachusetts, USA

10Department of Addiction research a and Therapy, Malibu Beach Recovery Center, Malibu Beach, California

11Department of Orthopaedic Surgery at the University of Pennsylvania, Philidelphia, Pennslyvania, USA

l2Addiction Recovery Resources, Inc., New Orleans, Louisiana, USA, Genomics HealthCare, LLC, Montebello, California, USA

*Corresponding Author:
Kenneth Blum
Department of Psychiatry and McKnight Brain Institute
University of Florida, College of Medicine
Gainesville, Florida, USA
E-mail: [email protected]

Received date: August 02, 2013; Accepted date:August 02, 2013; Published date: August 05, 2013

Citation: Blum K, Febo M, Giordano J, Hauser M, Oscar- Berman M, et al. (2013) Clinical Practices that can Combat Endemic Legal Opioid Dependence: Genetic Addiction Risk Score (GARS)™, KB220Z™, Comprehensive Analysis of Reported Drugs (CARD) and Electrotherapy. J Genet Syndr Gene Ther 4:e122. doi:10.4172/2157-7412.1000e122

Copyright: © 2013 Blum K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Genetic Syndromes & Gene Therapy

Iatrogenic prescription drug abuse in the United States caused ˜27,000 unintentional drug overdose deaths back in 2007 when 9 million individuals reported chronic use of opioid pain treatment [1,2]. The Reward Deficiency Solution System (RDSS) presented here brings together research into strategies being developed for clinicians to assist in avoidance of some of the unintended consequences of opioid pain treatment. Genetic mechanisms in the prefrontal cortex (PFC) and the mesolimbic “reward center” have a role in the moderation of pain sensitivity and tolerance and can be used to determine genetic addiction predisposition [3]. Patients at risk would benefit from non- addictive alternative treatments for pain and careful monitoring.

A pilot study of genetic addiction risk score (GARS) severity was conducted in 70 patients attending two independent addiction treatment centers. The percentage of prevalence of the risk alleles (DRD2=A1; DRD3 =Gly; DRD4= 3R or 7R; SLC6A3 (DAT) =10R; 5HTTLPR = L or LA; OPRMI = G; GABA 3 =181; MAO= 3R; and COMT=G) was calculated and an arbitrary severity score established based on the percentage of risk alleles present. Physiological “mechanisms of action” of H-Wave device stimulation (HWDS) have been investigated in animals and assessed in a recent meta-analysis. A natural dopaminergic agonist (KB200Z) has been evaluated using fMRI, and qEEG, in humans and most recently rodent models. Data from Comprehensive Analysis of Reported Drugs (CARD) 2010- 2011(n=2,919; total 5838 urine specimens) was analyzed for compliance to treatment and abstinence [4].

The GARS pilot found 14% low risk; 81% moderate risk and 5% high risk. HWDS was shown to reduce edema (stimulation of lymphatic smooth muscle fibers) provide loading to healing tissue and benefit tissue healing (by induction of nitric oxide (NO)-dependent microcirculation augmentation and angiogenesis -new blood vessels formation). Meta-analysis determined that HWDS reduced pain medication requirement, provided pain relief and promoted earlier functionality. KB220Z showed BOLD activation of dopaminergic pathways and PFC-cingulate gyrus activity regulation in humans. Finally, CARD analysis revealed significant differences in both compliance and abstinence rates. Opioid replacement programs compliance was best with Methadone 88% and Suboxone 92% but high non-abstinence ˜49% (opioids accounting for ˜ 47%).

GARS tests (including P450-associated with narcotic metabolism [5]) can identify patients with a predisposition to addiction early in treatment. Patients at risk will need a non- addictive alternative pain therapy like the electrotherapeutic H-Wave® device [6]. Another alternative KB200Z was engendered by the identification of the genetic therapeutic targets associated with Reward Deficiency Syndrome (RDS) [7]. This non-narcotic pharmacogenomic dopamine agonist can treat pain, improve pain tolerance and cognition, reduce craving and promote compliance [3]. Currently, we are under taking neuroimaging studies of KB220Z in rodents and an analysis of genetic risk for RDS in patients presenting with pain with and without associated RDS behaviors (n˜400). A positive association will support the incorporation of genotyping of pain patients, at entry, for opiate addiction risk. To reduce addiction morbidity and mortality in pain treatment we propose a RDSS: genetic testing for both narcotic metabolism and risk, non-addicting treatment alternatives; electrotherapy, dopaminergic activation KB220Z, careful monitoring and documentation of compliance and abstinence CARD coupled with the Revised Screener and Opioid Assessment (SOAPP-R) [8].

Conflict of Interest

Kenneth Blum, PhD is the holder of a number of patents involved with genetic testing and nutrigenomics and is currently- Managing Partner of IGENE, LLC and owns shares in Impact Genomics, Inc. the exclusive worldwide distributors of the GARS test and KB220Z respectively. He is a consultant Chief Scientific officer of G and G Healthcare Services LLC and Genomics Healthcare, LLC. He is on the Advisory Board of Dominion Diagnostics, LLC, Malibu Beach Recovery Center, Path Foundation, NY. He receives grants from Life Extension Foundation to Path Foundation. Mary Hauser is vice President of Dominion Diagnostics the commercial developer with IGENE LLC for the GARS test. Thomas Simpatico is on the Advisory Board of Dominion Diagnostics. Both Dr. Blum and Dr. DiNubile are paid consultants of Electronic Waveform Labs Huntington, Beach, California. No other conflict of interest.

Acknowledgements

Dr. Marcelo Febo is the recipient of NIH_NIDA Grant # DA019946. Dr. Kenneth Blum is the recipient of Life Extension Foundation grand to Path Foundation NY.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 10th International Conference on Genomics and Molecular Biology
    May 21-23, 2018 Barcelona, Spain
  • 5th International Conference on Human Genetics and Genetic Disorders September 21-22,2018 Philadelphia, USA Theme: Sharing Discoveries of the Future Human Genome
    September 21-22,2018 Philadelphia, USA

Article Usage

  • Total views: 11731
  • [From(publication date):
    August-2013 - Apr 22, 2018]
  • Breakdown by view type
  • HTML page views : 7958
  • PDF downloads : 3773
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version